![cardchecklist 391105 script · CIR acp s5-21 ON S5-36 a SPR S5-41 s5-77 DR S5-58 a R S5-5 acp OSPR S5-22 ON S5-37 C] S5-42 acp DR CIR apR a R S5-27 C] PR S-5-88 a R S5-47 CIN s5-64](https://static.fdocuments.in/doc/165x107/5f34fee96b83591bd77e360b/cardchecklist-391105-script-cir-acp-s5-21-on-s5-36-a-spr-s5-41-s5-77-dr-s5-58-a.jpg)
Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17...
9
undefined S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2- POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDY Speaker: Hans Wildiers Slide 1 / 17 Slide 2 / 17 Page 1
Transcript of Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17...
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 1 / 17
Slide 2 / 17
Page 1
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 3 / 17
Slide 4 / 17
Page 2
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 5 / 17
Slide 6 / 17
Page 3
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 7 / 17
Slide 8 / 17
Page 4
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 9 / 17
Slide 10 / 17
Page 5
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 11 / 17
Slide 12 / 17
Page 6
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 13 / 17
Slide 14 / 17
Page 7
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 15 / 17
Slide 16 / 17
Page 8
undefined
S5-05 TRASTUZUMAB EMTANSINE IMPROVES OVERALL SURVIVAL VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER: FINAL OVERALL SURVIVAL RESULTS FROM THE PHASE 3 TH3RESA STUDYSpeaker: Hans Wildiers
Slide 17 / 17
Page 9
